- Home
- RDCM vs GOSS Comparison
RDCM vs GOSS Comparison
Compare RDCM & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDCM
- GOSS
- Stock Information
- Founded
- RDCM 1985
- GOSS 2015
- Country
- RDCM Israel
- GOSS United States
- Employees
- RDCM N/A
- GOSS N/A
- Industry
- RDCM Computer peripheral equipment
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- RDCM Technology
- GOSS Health Care
- Exchange
- RDCM Nasdaq
- GOSS Nasdaq
- Market Cap
- RDCM 179.7M
- GOSS 188.6M
- IPO Year
- RDCM 1997
- GOSS 2019
- Fundamental
- Price
- RDCM $11.28
- GOSS $0.84
- Analyst Decision
- RDCM Strong Buy
- GOSS Strong Buy
- Analyst Count
- RDCM 2
- GOSS 4
- Target Price
- RDCM $15.00
- GOSS $7.50
- AVG Volume (30 Days)
- RDCM 26.7K
- GOSS 1.5M
- Earning Date
- RDCM 05-14-2025
- GOSS 05-06-2025
- Dividend Yield
- RDCM N/A
- GOSS N/A
- EPS Growth
- RDCM 79.17
- GOSS N/A
- EPS
- RDCM 0.43
- GOSS N/A
- Revenue
- RDCM $61,009,000.00
- GOSS $114,701,000.00
- Revenue This Year
- RDCM $14.93
- GOSS N/A
- Revenue Next Year
- RDCM $10.74
- GOSS $172.31
- P/E Ratio
- RDCM $26.23
- GOSS N/A
- Revenue Growth
- RDCM 18.23
- GOSS N/A
- 52 Week Low
- RDCM $8.52
- GOSS $0.50
- 52 Week High
- RDCM $15.98
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- RDCM 47.85
- GOSS 37.58
- Support Level
- RDCM $9.88
- GOSS $0.80
- Resistance Level
- RDCM $11.34
- GOSS $0.88
- Average True Range (ATR)
- RDCM 0.66
- GOSS 0.10
- MACD
- RDCM 0.04
- GOSS -0.01
- Stochastic Oscillator
- RDCM 68.97
- GOSS 20.24
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.